{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:06:28Z","timestamp":1781103988726,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Zai Lab"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40268-024-00490-6","type":"journal-article","created":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T09:01:43Z","timestamp":1728118903000},"page":"505-515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetics, Pharmacodynamics, and Safety of Intravenous Efgartigimod and Subcutaneous Efgartigimod PH20 in Healthy Chinese Participants"],"prefix":"10.1007","volume":"24","author":[{"given":"Shan","family":"Jing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Guglietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Noukens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonke","family":"Van Bragt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Reinhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,5]]},"reference":[{"key":"490_CR1","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.3389\/fimmu.2019.01540","volume":"10","author":"M Pyzik","year":"2019","unstructured":"Pyzik M, Sand KMK, Hubbard JJ, Andersen JT, Sandlie I, Blumberg RS. The neonatal Fc Receptor (FcRn): a misnomer? Front Immunol. 2019;10:1540. https:\/\/doi.org\/10.3389\/fimmu.2019.01540.","journal-title":"Front Immunol"},{"key":"490_CR2","doi-asserted-by":"publisher","first-page":"175628642199738","DOI":"10.1177\/1756286421997381","volume":"14","author":"MC Dalakas","year":"2021","unstructured":"Dalakas MC, Spaeth PJ. The importance of FcRn in neuro-immunotherapies: from IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. Ther Adv Neurol Disord. 2021;14:1756286421997381. https:\/\/doi.org\/10.1177\/1756286421997381.","journal-title":"Ther Adv Neurol Disord"},{"key":"490_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","volume":"82","author":"YA Heo","year":"2022","unstructured":"Heo YA. Efgartigimod: first approval. Drugs. 2022;82:341\u20138. https:\/\/doi.org\/10.1007\/s40265-022-01678-3.","journal-title":"Drugs"},{"key":"490_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.892534","volume":"13","author":"ES Ward","year":"2022","unstructured":"Ward ES, Gelinas D, Dreesen E, Van Santbergen J, Andersen JT, Silvestri NJ, et al. Clinical significance of serum albumin and implications of FcRn inhibitor treatment in IgG-mediated autoimmune disorders. Front Immunol. 2022;13: 892534. https:\/\/doi.org\/10.3389\/fimmu.2022.892534.","journal-title":"Front Immunol"},{"key":"490_CR5","doi-asserted-by":"crossref","unstructured":"Ostrovskaya O, Magdalena S, Ulrichts P, Trainor L, Verheesen P, Stoykov I. Efgartigimod: clinical development of a Novel FcRn antagonist in the treatment of autoimmune diseases. Presented at: 2023 Winter Clinical Dermatology Conference; January 13\u201318, 2023; Kohala Coast, HI.","DOI":"10.25251\/skin.7.supp.193"},{"key":"490_CR6","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/nbt1143","volume":"23","author":"C Vaccaro","year":"2005","unstructured":"Vaccaro C, Zhou J, Ober RJ, Ward ES. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol. 2005;23:1283\u20138. https:\/\/doi.org\/10.1038\/nbt1143.","journal-title":"Nat Biotechnol"},{"key":"490_CR7","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts P, Guglietta A, Dreier T, van Bragt T, Hanssens V, Hofman E, et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest. 2018;128:4372\u201386. https:\/\/doi.org\/10.1172\/JCI97911.","journal-title":"J Clin Invest"},{"key":"490_CR8","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20:526\u201336. https:\/\/doi.org\/10.1016\/S1474-4422(21)00159-9.","journal-title":"Lancet Neurol"},{"key":"490_CR9","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1016\/S0140-6736(23)01460-5","volume":"402","author":"CM Broome","year":"2023","unstructured":"Broome CM, McDonald V, Miyakawa Y, Carpenedo M, Kuter DJ, Al-Samkari H, et al. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2023;402:1648\u201359. https:\/\/doi.org\/10.1016\/S0140-6736(23)01460-5.","journal-title":"Lancet"},{"key":"490_CR10","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/ajh.25680","volume":"95","author":"AC Newland","year":"2020","unstructured":"Newland AC, Sanchez-Gonzalez B, Rejto L, Egyed M, Romanyuk N, Godar M, et al. Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. Am J Hematol. 2020;95:178\u201387. https:\/\/doi.org\/10.1002\/ajh.25680.","journal-title":"Am J Hematol"},{"key":"490_CR11","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","volume":"92","author":"JF Howard Jr","year":"2019","unstructured":"Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019;92:e2661\u201373. https:\/\/doi.org\/10.1212\/WNL.0000000000007600.","journal-title":"Neurology"},{"key":"490_CR12","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/bjd.20782","volume":"186","author":"M Goebeler","year":"2022","unstructured":"Goebeler M, Bata-Csorgo Z, De Simone C, Didona B, Remenyik E, Reznichenko N, et al. Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial. Br J Dermatol. 2022;186:429\u201339. https:\/\/doi.org\/10.1111\/bjd.20782.","journal-title":"Br J Dermatol"},{"key":"490_CR13","doi-asserted-by":"publisher","first-page":"6214","DOI":"10.1212\/WNL-.0000000000206324","volume":"102","author":"J Allen","year":"2024","unstructured":"Allen J, Basta I, Eggers C, Guptill J, Gwathmey K, Hewamadduma C, et al. Efficacy, safety, and tolerability of efgartigimod in patients with chronic inflammatory demyelinating polyneuropathy: results from the ADHERE trial (PL5.002). Neurology. 2024;102:6214. https:\/\/doi.org\/10.1212\/WNL-.0000000000206324.","journal-title":"Neurology"},{"key":"490_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.863095","volume":"13","author":"M Maho-Vaillant","year":"2022","unstructured":"Maho-Vaillant M, Sips M, Golinski ML, Vidarsson G, Goebeler M, Stoevesandt J, et al. FcRn antagonism leads to a decrease of desmoglein-specific B cells: secondary analysis of a phase 2 study of efgartigimod in pemphigus vulgaris and pemphigus foliaceus. Front Immunol. 2022;13: 863095. https:\/\/doi.org\/10.3389\/fimmu.2022.863095.","journal-title":"Front Immunol"},{"key":"490_CR15","unstructured":"argenx and Zai Lab announce approval of VYVGART\u00ae (efgartigimod alfa injection) for generalized myasthenia gravis in China. [media release]. 2022. https:\/\/www.biospace.com\/article\/releases\/argenx-and-zai-lab-announce-approval-of-vyvgart-efgartigimod-alfa-injection-for-generalized-myasthenia-gravis-in-china\/. Accessed 23 Aug 2024."},{"key":"490_CR16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40263-023-01000-z","volume":"37","author":"YA Heo","year":"2023","unstructured":"Heo YA. Efgartigimod alfa in generalised myasthenia gravis: a profile of its use. CNS Drugs. 2023;37:467\u201373. https:\/\/doi.org\/10.1007\/s40263-023-01000-z.","journal-title":"CNS Drugs"},{"key":"490_CR17","unstructured":"United States Food and Drug Administration. VYVGART\u00ae HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) injection, for subcutaneous use. argenx. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761304s000lbl.pdf. Accessed 04 Aug 2023."},{"key":"490_CR18","unstructured":"Halozyme announces argenx receives FDA approval for VYVGART\u00ae Hytrulo with ENHANZE\u00ae for subcutaneous use in generalized myasthenia gravis [media release]. 2023. https:\/\/www.prnewswire.com\/news-releases\/halozyme-announces-argenx-receives-fda-approval-for-vyvgart-hytrulo-with-enhanze-for-subcutaneous-use-in-generalized-myasthenia-gravis-301855994.html. Accessed 23 Aug 2024."},{"key":"490_CR19","unstructured":"argenx announces European Commission approval of subcutaneous VYVGART\u00ae (efgartigimod alfa) for generalized myasthenia gravis. 2022. https:\/\/flanders.bio\/en\/news\/argenx-european-commission-approval-subcutaneous-vyvgart. Accessed 12 Dec 2023."},{"key":"490_CR20","unstructured":"argenx Announces Approval of VYVDURA\u00ae (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis. 2024. https:\/\/ir.zailaboratory.com\/news-releases\/news-release-details\/argenx-announces-approval-vyvdurar-efgartigimod-alfa-and\/. Accessed 22 Apr 2024."},{"key":"490_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.17925\/USN.2022.18.2.127","volume":"18","author":"F Vanoli","year":"2022","unstructured":"Vanoli F, Mantegazza R. Efgartigimod: a first-in-class investigational antibody fragment for the treatment of generalized myasthenia gravis. TouchRev Neurol. 2022;18:127\u201332. https:\/\/doi.org\/10.17925\/USN.2022.18.2.127.","journal-title":"TouchRev Neurol."},{"key":"490_CR22","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1007\/s00415-022-11517-w","volume":"270","author":"F Sacca","year":"2023","unstructured":"Sacca F, Barnett C, Vu T, Peric S, Phillips GA, Zhao S, et al. Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT). J Neurol. 2023;270:2096\u2013105. https:\/\/doi.org\/10.1007\/s00415-022-11517-w.","journal-title":"J Neurol"},{"key":"490_CR23","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1007\/s12325-019-01101-6","volume":"36","author":"I Usach","year":"2019","unstructured":"Usach I, Martinez R, Festini T, Peris JE. Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv Ther. 2019;36:2986\u201396. https:\/\/doi.org\/10.1007\/s12325-019-01101-6.","journal-title":"Adv Ther"},{"key":"490_CR24","doi-asserted-by":"publisher","first-page":"1229112","DOI":"10.3389\/fneur.2023.1229112","volume":"14","author":"V Bhandari","year":"2023","unstructured":"Bhandari V, Bril V. FcRn receptor antagonists in the management of myasthenia gravis. Front Neurol. 2023;14:1229112. https:\/\/doi.org\/10.3389\/fneur.2023.1229112.","journal-title":"Front Neurol"},{"key":"490_CR25","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s40120-022-00345-9","volume":"11","author":"C Yan","year":"2022","unstructured":"Yan C, Duan RS, Yang H, Li HF, Zou Z, Zhang H, et al. Therapeutic effects of batoclimab in Chinese patients with generalized myasthenia gravis: a double-blinded, randomized, placebo-controlled phase II study. Neurol Ther. 2022;11:815\u201334. https:\/\/doi.org\/10.1007\/s40120-022-00345-9.","journal-title":"Neurol Ther."},{"key":"490_CR26","doi-asserted-by":"publisher","first-page":"251584142110277","DOI":"10.1177\/25158414211027760","volume":"13","author":"CJ Men","year":"2021","unstructured":"Men CJ, Kossler AL, Wester ST. Updates on the understanding and management of thyroid eye disease. Ther Adv Ophthalmol. 2021;13:25158414211027760. https:\/\/doi.org\/10.1177\/25158414211027760.","journal-title":"Ther Adv Ophthalmol."},{"key":"490_CR27","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1210\/clinem\/dgad381","volume":"108","author":"GJ Kahaly","year":"2023","unstructured":"Kahaly GJ, Dolman PJ, Wolf J, Giers BC, Elflein HM, Jain AP, et al. Proof-of-concept and randomized, placebo-controlled trials of an FcRn inhibitor, batoclimab, for thyroid eye disease. J Clin Endocrinol Metab. 2023;108:3122\u201334. https:\/\/doi.org\/10.1210\/clinem\/dgad381.","journal-title":"J Clin Endocrinol Metab"},{"key":"490_CR28","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Druzdz A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023;22:383\u201394. https:\/\/doi.org\/10.1016\/S1474-4422(23)00077-7.","journal-title":"Lancet Neurol"},{"key":"490_CR29","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan1208","author":"P Kiessling","year":"2017","unstructured":"Kiessling P, Lledo-Garcia R, Watanabe S, Langdon G, Tran D, Bari M, et al. The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study. Sci Transl Med. 2017;9:eaan1208.\u00a0https:\/\/doi.org\/10.1126\/scitranslmed.aan1208.","journal-title":"Sci Transl Med."},{"key":"490_CR30","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207937","volume":"102","author":"C Antozzi","year":"2024","unstructured":"Antozzi C, Guptill J, Bril V, Gamez J, Meuth SG, Nowak RJ, et al. Safety and efficacy of nipocalimab in patients with generalized myasthenia gravis: results from the randomized phase 2 vivacity-MG study. Neurology. 2024;102: e207937. https:\/\/doi.org\/10.1212\/WNL.0000000000207937.","journal-title":"Neurology"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-024-00490-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-024-00490-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-024-00490-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T03:12:09Z","timestamp":1734491529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-024-00490-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,5]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["490"],"URL":"https:\/\/doi.org\/10.1007\/s40268-024-00490-6","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,5]]},"assertion":[{"value":"1 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by the sponsor, Zai Lab (Shanghai) Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"A.G., a former argenx employee, is a consultant to argenx currently. J.N. and T.V.B. are consultants to argenx. X.G., J.L., L.W., J.C., H.R., and X.P. are employees of Zai Lab, and they hold stock options and shares in Zai Lab. The other authors have no relevant financial or nonfinancial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Both studies were conducted in accordance with the Good Clinical Practice of the International Conference for Harmonisation guidelines, applicable local regulatory requirements, and the principles of the Declaration of Helsinki. IV study, approval number 2021-17, approval date 7 June 2021; SC study, approval number 2021-0236-02, approval date 29 June 21.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All study participants provided written informed consent prior to the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All authors approved the manuscript for publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Please contact Zai Lab (Shanghai) Co., Ltd., for data inquiries.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors equally contributed to the study conception, data visualization, review and editing of the manuscript, analysis of the data, conduct of research investigations, development of methods, and administration of projects.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}